ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Werewolf Therapeutics Inc

Werewolf Therapeutics Inc (HOWL)

0.3513
0.0073
(2.12%)
Closed June 21 3:00PM
0.3513
0.00
(0.00%)
After Hours: 4:20PM

Werewolf Therapeutics Inc (HOWL) Options

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.000.050.050.000.00 %01,279-
5.000.000.000.260.260.000.00 %0126-
7.500.000.000.240.240.000.00 %0216-

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.002.102.100.000.00 %00-
5.000.000.004.804.800.000.00 %00-
7.500.000.007.307.300.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ADTXAditxt Inc
US$ 0.01
(127.27%)
5.38B
LNKSLinkers Industries Ltd
US$ 2.6509
(65.68%)
69.88M
CASTFreeCast Inc
US$ 8.0101
(55.54%)
113.02M
CDTCDT Equity Inc
US$ 1.0101
(45.76%)
249.47M
APWCAsia Pacific Wire and Cable Corporation Ltd
US$ 2.02
(45.32%)
48.09M
INLFINLIF Limited
US$ 0.1533
(-64.95%)
131.52M
SNBRSleep Number Corporation
US$ 0.2152
(-44.82%)
52.75M
YYGHYY Group Holding Ltd
US$ 0.0791
(-38.63%)
82.04M
LABTLakewood-Amedex Biotherapeutics Inc
US$ 0.3852
(-36.03%)
1.83M
EHGOEshallgo Inc
US$ 1.895
(-34.43%)
2.2M
ADTXAditxt Inc
US$ 0.01
(127.27%)
5.38B
GDCGD Culture Group Ltd
US$ 0.0177
(-16.90%)
931.09M
SPCXSpace Exploration Technologies Corporation
US$ 185.00
(-3.56%)
272.29M
MRVLMarvell Technology Inc
US$ 310.58
(7.27%)
251.21M
CDTCDT Equity Inc
US$ 1.0101
(45.76%)
249.47M

HOWL Discussion

View Posts
mrfrederikson mrfrederikson 2 months ago
https://aacrjournals.org/cancerimmunolres/article-abstract/14/3/434/774857/WTX-124-a-Conditionally-Activated-Wild-Type-IL2?redirectedFrom=fulltext
πŸ‘οΈ0
tw0122 tw0122 8 months ago
$2.27 fast track means money coming to them..  Company has received Fast Track Designation for the use of WTX-124 for the potential treatment of patients with locally advanced or metastatic cutaneous melanoma after standard of care immunotherapy. WTX-124 is a conditionally activated interleukin 2 (IL-2) INDUKINE therapy. Fast Track Designation is intended to expedite the development of drugs to address a serious unmet medical need and provide opportunities for frequent FDA interactions.Werewolf is evaluating WTX-124 in a Phase 1/1b open-label, multicenter study including single-agent and combination arms with pembrolizumab for the treatment of multiple advanced solid tumors (NCT05479812). WTX-124 was designed to stimulate a powerful anti-tumor immune response by providing IL-2 selectively to the tumor microenvironment while decreasing the systemic toxicities that have been observed with other IL-2 immune therapies.β€œAt Werewolf we are focusing on efforts to address the high unmet need of cancer patients, and we believe there is significant opportunity with WTX-124 for the potential treatment of advanced cancers,” said Daniel J. Hicklin, PhD, President and Chief Executive Officer of Werewolf. β€œWe are encouraged by this Fast Track Designation as an important milestone for the WTX-124 program and because it underscores the urgent need for patients with relapsed/refractory melanoma where treatment options are limited. In the fourth quarter, we anticipate sharing preliminary data from the ongoing WTX-124 Phase 1/1b clinical trial, including in patients with cutaneous melanoma, and engaging with the FDA regarding the potential registration strategy for this agent.”The FDA’s Fast Track program is designed to facilitate the development and expedite the review of investigational drugs that demonstrate the potential to address unmet medical needs in serious or life-threatening conditions. Product candidates with Fast Track designation are eligible for priority review, the opportunity for a rolling Biologics License Application (BLA), and accelerated approval if relevant criteria are met. The Fast Track designation for WTX-124 was granted based on data in cutaneous melanoma patients previously treated with immune checkpoint inhibitor therapy who demonstrated clinically meaningful anti-tumor activity with a tolerable safety profile. The designation could enable Werewolf to interact more frequently with the FDA to discuss WTX-124’s development path.
πŸ‘οΈ0
tw0122 tw0122 8 months ago
$2.05 Halloween time again let the Werewolf out
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
HOWL under $2
πŸ‘οΈ0
tw0122 tw0122 2 years ago
Halloween is here again give it another howl. Flip time coming $4.45
πŸ‘οΈ0
tw0122 tw0122 2 years ago
$3.65 + 30% HOWLing a little some.. Title: INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in Murine Syngeneic Tumor Models
Abstract Number: 955
Session Date and Time: Friday, Nov. 8, 2024; 9 a.m.–8:30 p.m.
Location: George R. Brown Convention Center - Exhibit Halls A B

Title: The tumor-activated IL-12 prodrug WTX-330 expanded/activated tumor infiltrating lymphocytes and caused tumor regression in patients with refractory solid tumors: Interim data from an ongoing Ph1 study
Abstract Number: 672
Session Date and Time: Saturday, Nov. 9, 2024; 9 a.m.–8:30 p.m.
Location: George R. Brown Convention Center - Exhibit Halls A B

About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf leverages its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. The Company’s INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Werewolf’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 as a single agent in multiple tumor types and Non-Hodgkin Lymphoma. To learn more visit www.werewolftx.com.

WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.

πŸ‘οΈ0
Monksdream Monksdream 2 years ago
HOWL under $3
πŸ‘οΈ0
Monksdream Monksdream 2 years ago
HOWL under $3
πŸ‘οΈ0
Monksdream Monksdream 2 years ago
HOWL under $10
πŸ‘οΈ0
Monksdream Monksdream 2 years ago
HOWL new 52 week high
πŸ‘οΈ0
Pt3 Pt3 3 years ago
Yea your gap and trapped make me buy caud instead of this
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
HOWL todays algo patented Gap & Trap on Phase #1 news
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
Werewolf Therapeutics soars 52% premarket after presentsing preliminary monotherapy data from Phase 1/1b clinical trial establishing proof of mechanism for WTX-124$HOWL#AInvest #Ainvest_Wire #trade #source #wallstreet
View more: https://t.co/aTzfU7GqUS pic.twitter.com/rClSWzl2IS— AInvest Wire (@Ainvest_Wire) November 3, 2023
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
$howl flying https://finviz.com/quote.ashx?t=HOWL&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/HOWL
πŸ‘οΈ0
tw0122 tw0122 3 years ago
$3 + otw Halloween is here give it a HOWL
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
dip
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
dip
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
watching
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
soon
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
insert dd
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
can be big
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
wow
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
wow
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
hold
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
slow
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
slow
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
agreed
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
like thiks
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
off radar
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
catchy name
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 years ago
catchy name
πŸ‘οΈ0
surf1944 surf1944 3 years ago
https://stockcharts.com/h-sc/ui?s=howl&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/howl/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/howl/opinion
πŸ‘οΈ0
Mr. Zen Mr. Zen 3 years ago
Watch list addition, this has the potential to run, just waiting for all the pieces of the puzzle to come together.

β€œThese promising preclinical data add to a growing body of evidence demonstrating the potential of WTX-330 to drive targeted anti-tumor immune responses selectively in the tumor microenvironment (TME),” said Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf Therapeutics. β€œThis morning, in our Third Quarter 2022 release, we announced that the FDA has granted clearance of the investigational new drug (IND) application for WTX-330. We are excited to advance WTX-330 into the clinic and to continue developing a pipeline of novel proinflammatory cytokine therapies that have the potential to change the lives of cancer patients.”
πŸ‘οΈ0
makinezmoney makinezmoney 3 years ago
$HOWL: Hey thanks....... now 3.20.

Only getting better right ??


Enjoy those profits.





GO $HOWL
πŸ‘οΈ0
Makk1 Makk1 3 years ago
Good call here, looking very good
πŸ‘οΈ0
makinezmoney makinezmoney 3 years ago
$HOWL: Looks like its turning...... now 2.25

Let see if volume pushes it up.


The setup is nice


GO $HOWL
πŸ‘οΈ0
bobbo5 bobbo5 4 years ago
I agree and it looks like share price has been moving up this past week
πŸ‘οΈ0
dia76ca dia76ca 4 years ago
Very interesting company. I like it's chances.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock